Sanara MedTech (SMTI) agrees to MiMedx takeover, targeting year-end close
Sanara MedTech Inc. (SMTI) has entered into a definitive agreement to be acquired by MiMedx Group, Inc., aiming to create a leading regenerative medicine company. The transaction, which is subject to regulatory and stockholder approvals, is expected to close by the end of the year. Both companies will operate independently until closing, with existing distributor agreements remaining unchanged.
MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal
MiMedx Group has clarified the termination fees for its merger with Sanara MedTech Inc., stating Sanara would owe $9.66 million in specific cases and MiMedx $22.54 million if it fails to close. The deal offers Sanara shareholders $33.00 cash plus 0.4735 shares of MiMedx common stock per share, and MiMedx has secured a $300 million loan to finance the acquisition. The transaction is subject to Sanara stockholder and antitrust approvals, with a voting agreement covering 38.9% of Sanara's voting power already in place.
Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees
Sanara MedTech Inc. has confirmed the terms of its merger with MiMedx Group, Inc., where each Sanara share will convert into $33.00 in cash and 0.4735 shares of MiMedx common stock, valued at $2.00 per share. This amendment also corrects previously misstated termination fees, with Sanara owing $9,660,336.00 to MiMedx in specific scenarios and MiMedx owing Sanara $22,540,785.00 if it fails to close the deal. The merger is supported by a voting agreement covering approximately 38.9% of Sanara's voting power and is subject to regulatory and stockholder approvals with an outside date of July 29, 2027.
MiMedx Group, Inc Revenue Breakdown – NASDAQ:MDXG
This article provides a revenue breakdown for MiMedx Group, Inc (NASDAQ: MDXG). Last year, the company generated $418.63 million USD in total revenue, with its Wound segment being the top performer, contributing $276.33 million USD. The United States was the greatest regional contributor to revenue, accounting for the entire $418.63 million USD.
MiMedx Group Inc (MDXG) Stock News Today
This article from TradingKey provides current stock information for MiMedx Group Inc (MDXG), including its stock price, market cap, and P/E ratio. It notes that more news regarding MDXG's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for financial data and future news updates for the company.
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear
MiMedx Group's recent earnings might seem weak, but a deeper analysis reveals a stronger financial position than initially perceived. The company's accrual ratio of -0.36 indicates that its free cash flow significantly exceeded its reported statutory profit, suggesting an understatement of its true earnings potential. Additionally, MiMedx Group is experiencing strong EPS growth, further supporting a more optimistic outlook.
MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for MiMedx Group Inc (MDXG), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $12.00. Based on 5 analysts, the stock has a "Buy" rating with a potential upside of 61.29%. Key financial expectations include a forecasted revenue of $70.25M for the next quarter and an expected EPS of -$0.02.
Lazard Asset Management LLC Sells 264,718 Shares of MiMedx Group, Inc $MDXG
Lazard Asset Management LLC significantly reduced its stake in MiMedx Group, Inc. (MDXG) by selling 264,718 shares, a 38.6% decrease, though it still holds 420,706 shares. Despite this sale, other major institutional investors like Vanguard, State Street, Paradigm Capital, and Renaissance Technologies increased their holdings in the biopharmaceutical company. MiMedx Group's stock recently rose 3.4%, and the company met EPS estimates while exceeding revenue expectations, maintaining a "Moderate Buy" consensus rating from analysts.
MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data
MiMedx Group (NASDAQ: MDXG) had 799 employees globally as of March 2026, representing a 1.0% decline since 2023. The company is actively hiring, with 40 active job postings in 2026, though new postings are slowing. The workforce is primarily concentrated in the United States, and the largest functional groups are Finance and Operations, and Engineering.
Renaissance Technologies LLC Has $11.93 Million Stake in MiMedx Group, Inc $MDXG
Renaissance Technologies LLC increased its stake in MiMedx Group, Inc (MDXG) by 22.4% in the first quarter, now holding 3.02 million shares valued at $11.93 million, representing 2.03% of the company. Despite some recent analyst price target reductions and downgrades, the stock maintains a "Moderate Buy" consensus rating with a target price of $8.50. MiMedx reported Q2 revenue of $64.36 million and an EPS of negative $0.05, matching analyst expectations.
MIMEDX to Acquire Sanara MedTech
MIMEDX Group, Inc. announced its definitive merger agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million. This acquisition aims to significantly expand MIMEDX’s surgical footprint, nearly doubling its surgical revenue, and creating a leading regenerative medicine company. The combined entity is expected to achieve over $400 million in total revenue by 2027 with an Adjusted EBITDA margin exceeding 20%, driven by anticipated cost synergies and an expanded product portfolio.
Q2 2026 MiMedx Group Inc Earnings Call and to Acquire Sanara MedTech Transcript
MiMedx Group Inc (MDXG) reported strong sequential revenue growth in Q2 2026, with surgical business growing 15% year-over-year. The company announced its acquisition of Sanara MedTech, which is expected to be immediately accretive and transformational, aiming for over $400 million in revenue and 20%+ adjusted EBITDA margin by 2027 for the combined entity. Despite these positive developments, net sales decreased 35% year-over-year due to Medicare reimbursement changes, and the wound care market continues to face challenges.
Sanara MedTech (SMTI) plans business combination with MiMedx Group to build regenerative leader
Sanara MedTech (SMTI) has announced a proposed business combination with MiMedx Group, Inc., aiming to establish a leading regenerative medicine company focused on surgical and wound care applications. The transaction is expected to close by year-end, pending regulatory and shareholder approvals. Until then, both companies will operate independently.
MiMedx to acquire Sanara MedTech for $350M
MiMedx Group is set to acquire Sanara MedTech in a cash-and-stock transaction valued at approximately $350 million. Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MiMedx common stock per share. The acquisition aims to accelerate MiMedx's growth in surgical end markets, with combined 2027 revenue projected to exceed $400 million and an adjusted EBITDA margin over 20%.
MiMedx Group Q2 Earnings Call Highlights
MiMedx Group announced its Q2 results and the acquisition of Sanara MedTech for $35 per share, expecting the deal to close by the end of 2026. This acquisition will significantly shift MiMedx's revenue mix towards surgical products, expanding its market opportunity by an estimated $4 billion. The combined company is projected to generate over $400 million in revenue in 2027 with double-digit growth and at least $20 million in annualized cost synergies.
ETFs Investing in MiMedx Group, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of MiMedx Group, Inc. (MDXG). It provides a detailed table with each ETF's market value of MDXG holdings, weight in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify accessible and lower-risk opportunities to invest in MiMedx Group, Inc. indirectly through ETFs.
MiMedx Group (SMTI) details Sanara MedTech buyout and 2027 profit goals
MiMedx Group announced its plan to acquire Sanara MedTech for $35 per share, aiming to combine Sanara's surgical revenue with MiMedx's soft-tissue surgical franchise and achieve at least $20 million in annual cost synergies. Despite a 35% year-over-year net sales drop in Q2 2026 due to Medicare reimbursement cuts, MiMedx reported a 9% sequential increase, with surgical revenue growing 15%. The acquisition is expected to boost combined 2027 revenue above $400 million and adjusted EBITDA margins to over 20%.
MiMedx: Q2 Earnings Snapshot
This article provides a brief snapshot of MiMedx's Q2 earnings. No specific financial details or further information about the earnings are included in the provided content.
MiMedx Group to Acquire Sanara MedTech in Merger
MiMedx Group announced its agreement to acquire Sanara MedTech in a cash-and-stock merger, valuing Sanara at $35 per share, representing approximately $350 million in enterprise value and a 46% premium. This acquisition aims to nearly double MiMedx's surgical revenue, enhance profitability, and generate over $20 million in cost synergies, positioning the combined entity as a leading regenerative medicine platform. The deal, expected to close by year-end, has been unanimously approved by both boards.
MiMedx Group Q2 Earnings Call Highlights
MiMedx Group (NASDAQ:MDXG) announced its agreement to acquire Sanara MedTech for $35 per share, a move expected to significantly increase surgical revenue and market opportunity, with the combined company projecting over $400 million in revenue by 2027. The acquisition, financed by a $300 million term loan, is anticipated to shift MiMedx's revenue mix to about 75% surgical products. MiMedx reported Q2 sales of $64 million, up 9% sequentially, and maintained its standalone 2026 outlook despite a sharp annual decline in wound-care revenue due to Medicare reimbursement changes.
Transcript : MiMedx Group, Inc., Q2 2026 Earnings Call, Jul 29, 2026
This article is a transcript of MiMedx Group, Inc.'s Q2 2026 Earnings Call, which took place on July 29, 2026. The content is primarily a message from the operator indicating the start of the conference call. The full transcript is reserved for subscribers.
MiMedx: Q2 Earnings Snapshot
This article is an earnings snapshot for MiMedx, typically providing a brief overview of the company's financial performance for the second quarter. Due to the lack of content, specific details about the earnings are not available.
MIMEDX to Acquire Sanara MedTech
MIMEDX announced its definitive merger agreement to acquire Sanara MedTech in a cash and stock transaction valued at $35 per share, totaling approximately $350 million. This acquisition aims to create a leading regenerative medicine company, significantly expanding MIMEDX’s surgical footprint and is expected to be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin, anticipating over $20 million in cost synergies. The combined entity is projected to achieve over $400 million in total revenue and an Adjusted EBITDA margin exceeding 20% by 2027.
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MIMEDX (Nasdaq: MDXG) announced its second quarter 2026 operating and financial results, reporting net sales of $64 million, a 35% decrease year-over-year, largely due to Medicare reimbursement changes impacting its Wound business. Despite a strong 15% growth in its Surgical franchise, the company posted a net loss of $15 million. Alongside these results, MIMEDX announced its intention to acquire Sanara MedTech (Nasdaq: SMTI) for approximately $350 million, aiming to accelerate long-term growth and shareholder value.
MiMedx Group (Nasdaq: MDXG) posts Q2 loss, plans $350M Sanara acquisition
MiMedx Group reported sharply weaker Q2 2026 results with a net loss of $14.84 million, a significant drop from a prior-year profit, primarily due to a 61.1% decline in Wound revenue following Medicare reimbursement changes. Despite a 15.1% increase in Surgical revenue, overall net sales fell 34.7% to $64.36 million. The company also announced plans to acquire Sanara MedTech for approximately $350 million, financed by a mix of cash, stock, and a new $300 million term loan.
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MIMEDX reported second-quarter 2026 net sales of $64 million, a decrease of 35% year-over-year, primarily due to a 61% decline in Wound sales impacted by Medicare reimbursement changes, despite 15% growth in its Surgical franchise. The company also announced plans to acquire Sanara MedTech Inc. for approximately $350 million, aiming to accelerate its surgical market expansion and reiterated its full-year 2026 net sales guidance of $260-290 million.
MIMEDX GROUP, INC. Q2 2026: Revenue $64.36M, EPS ($0.1) — 10-Q Summary
MIMEDX GROUP, INC. (MDXG) reported second-quarter 2026 results, showing a significant decline in revenue and a net loss, primarily due to Medicare reimbursement changes and reduced wound-product sales. Revenue fell to $64.36M from $98.61M year-over-year, leading to a diluted EPS of ($0.1). The company implemented cost-reduction initiatives and focused on surgical product growth and new commercial activities to mitigate the impact.
MiMedx: Q2 Earnings Snapshot
MiMedx Group Inc. (MDXG) reported a second-quarter loss of $14.8 million, or 10 cents per share, with adjusted losses at 5 cents per share. The biomaterials developer achieved revenue of $64.4 million for the period and projects full-year revenue between $260 million and $290 million. This financial update was generated using data from Zacks Investment Research.
MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for MiMedx Group Inc (MDXG), highlighting its current earnings forecast score of 8.00 and an average price target of $12.00. Based on analysis from 5 analysts, the stock is rated as a "Buy" with an expected revenue of $63.46M for the next quarter. The company's previous quarter's EPS was $0.10, with the next quarter's EPS expected to be -$0.05.
MiMedx Group Inc (MDXG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of MiMedx Group Inc's (MDXG) stock performance, market capitalization, and P/E ratio. It specifically notes that the company has not distributed any dividends over the past five years. The page indicates financial and corporate information for MDXG available on the TradingKey platform.
MiMedx Group Inc (MDXG) Cash Flow
This article provides a detailed cash flow statement for MiMedx Group Inc (MDXG), covering quarterly and annual data up to FY2026Q1. It breaks down various cash flow components including operating, investing, and financing activities, along with changes in working capital and specific asset transactions. The report also includes FAQs explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow in relation to MDXG's financial performance.
MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070
This article provides a detailed financial overview of MiMedx Group Inc. (MDXG), presenting its latest stock price, market cap, and P/E ratio, alongside comprehensive financial statements including income statement, balance sheet, and cash flow statement. It highlights key financial indicators, historical quarterly and annual performance data, upcoming earnings dates, and analyst ratings, giving investors an in-depth view of the company's financial health and performance. The article also includes a FAQ section answering common questions based on the company's FY2025 earnings report.
MiMedx Group, Inc Revenue Breakdown – BOATS:MDXG
MiMedx Group, Inc. (MDXG) last year generated $418.63 million in revenue, with its top-performing segment, Wound, contributing $276.33 million. The United States was the primary geographic contributor, accounting for the entire $418.63 million in revenue last year, showing an increase from $348.88 million the previous year.
MiMedx Group Inc (MDXG) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of MiMedx Group Inc (MDXG), noting its current valuation score of 6.65 and its position within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, comparing it to historical highs and lows, while also indicating that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed.
MiMedx Group Inc (MDXG) Financial Health: Profitability & Balance Sheet Analysis
MiMedx Group Inc (MDXG) has a robust financial status with a score of 8.21, ranking highly in the Biotechnology & Medical Research industry. Despite this, its latest quarterly revenue decreased by 33.12% year-over-year, and net profit saw a 254.63% decrease. The report highlights undisclosed data for several financial dimensions like cash and cash equivalents, total assets, operating profit, and free cash flow.
MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070
MiMedx Group Inc. (MDXG) shows strong fundamentals and high growth potential, with its valuation assessed as fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts have given it a "Buy" rating with a target price of 6.60. Despite good market performance, the stock is currently trading sideways, making it suitable for range-bound swing trading.
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MIMEDX announced it will report its Q2 2026 operating and financial results after market close on Wednesday, July 29, 2026. The senior management team will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be available for approximately 30 days on the Company’s website.
MiMedx Group, Inc (MDXG) Investor Outlook: Exploring a 52.42% Potential Upside Amidst Biotech Innovations
MiMedx Group, Inc. (MDXG) offers a potential 52.42% upside for investors, driven by its specialization in placental tissue allografts and innovative healthcare solutions. Despite a reported revenue growth rate of -33.10%, the company boasts a strong return on equity and free cash flow. Analysts are bullish, with an average price target of $6.60, indicating significant growth potential in the biotech sector.
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its Q2 2026 operating and financial results after market close on July 29, 2026. The company's senior management will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. A replay of the webcast will be available on the MiMedx website for approximately 30 days.
MIMEDX will review second-quarter results in a July 29 webcast
MiMedx (Nasdaq: MDXG) announced it will release its second-quarter 2026 operating and financial results after market close on Wednesday, July 29, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. A replay of the webcast will be available for approximately 30 days on the MIMEDX website.
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its second-quarter 2026 operating and financial results after market close on Wednesday, July 29, 2026. The company's senior management will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can access the event via webcast or conference call using provided details.
MiMedx Group (MDXG) Cantor Global Healthcare Conference 2025 Summary
This summary details MiMedx Group's (MDXG) participation in the Cantor Global Healthcare Conference 2025, highlighting its focus on wound and surgical healing solutions derived from birth tissue. The company discussed its strategic priorities, including expanding patient reach and growing its business, while navigating a positive regulatory and reimbursement environment with anticipated changes. MiMedx also emphasized its surgical business expansion and innovation pipeline, focusing on generating clinical evidence and exploring partnerships for further growth.
Form 4 MiMedx Group Inc For: 7 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for MiMedx Group Inc. on July 7th. It indicates that the company's stock symbol is MDXG, which experienced a 1.67% increase. The content provided is primarily a placeholder for the actual Form 4 details, surrounded by general financial market information, news headlines, and market data from Investing.com.
Form 4 MiMedx Group Inc For: 7 July By Investing.com
This article reports on a Form 4 filing for MiMedx Group Inc, dated July 7th, as published by Investing.com. It is a brief news item indicating a regulatory disclosure for the company. The article includes the stock symbol MDXG.
MIMEDX (MDXG) CFO has shares withheld to cover RSU tax liability
MIMEDX Group, Inc.'s CFO, Doug Rice, reported a routine share disposition where 12,749 shares of common stock were withheld at $3.95 per share to cover tax liabilities upon the vesting of restricted stock units. This transaction is considered an automatic share disposition for tax obligations rather than a discretionary open-market buy or sell. Following this event, Rice directly holds 399,566 shares of MIMEDX common stock.
If You Invested $1,000 in Mimedx Group Inc (MDXG)
This article analyzes the historical performance of a $1,000 investment in Mimedx Group Inc (MDXG) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed company profile, including its focus on regenerative medicine and advanced wound care, product portfolio, clinical evidence, market applications, operations, regulatory context, corporate governance, and current financial metrics.
MiMedx Group, Inc.(NasdaqCM: MDXG) added to Russell 2000 Value Benchmark
MiMedx Group, Inc. (NasdaqCM: MDXG) has been added to the Russell 2000 Value Benchmark, according to a report published on June 29, 2026. This news comes alongside several other index adjustments for the company on the same day and preceding days, indicating a re-evaluation of its classification within various Russell benchmarks. The article also provides a company profile, financial ratings, and analyst consensus for MiMedx Group.
MiMedx Group, Inc.(NasdaqCM: MDXG) dropped from Russell 2000 Growth Benchmark
MiMedx Group, Inc. (NasdaqCM: MDXG), a placental biologics company, has been removed from the Russell 2000 Growth Benchmark. This news comes amidst recent product launches like G4Derm Plus and Choriofix, and a strategic move to eliminate the COO role for cost savings. The company's stock has seen a 42.69% decrease year-to-date, despite analysts' consensus to "BUY" with an average target price significantly higher than its current close.
MDXG - Mimedx Group Inc Latest SEC Filings
This article provides a detailed financial overview of Mimedx Group Inc (MDXG), including its latest stock performance, key financial metrics, market capitalization, and various valuation ratios. It also lists insider and institutional ownership, profitability, and sales growth figures, giving a comprehensive snapshot of the company's current financial health and market position.
MiMedx Group, Inc.(NasdaqCM: MDXG) added to Russell 2000 Value-Defensive Index
MiMedx Group, Inc. (NasdaqCM: MDXG) has been added to the Russell 2000 Value-Defensive Index. This announcement follows recent news where the company was dropped from both the Russell 2000 Growth Benchmark and the Russell 3000E Growth Benchmark. The company specializes in placental biologics for wound care, burn, and surgical sectors.
